Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to $15.4 million.

  • Regenerative Medical Technology's Accumulated Expenses rose 7272.21% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 7272.21%. This contributed to the annual value of $10.5 million for FY2024, which is 5922.74% up from last year.
  • Regenerative Medical Technology's Accumulated Expenses amounted to $15.4 million in Q3 2025, which was up 7272.21% from $12.4 million recorded in Q2 2025.
  • Regenerative Medical Technology's Accumulated Expenses' 5-year high stood at $15.4 million during Q3 2025, with a 5-year trough of $22162.0 in Q4 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $6.2 million (2023), whereas its average is $6.1 million.
  • In the last 5 years, Regenerative Medical Technology's Accumulated Expenses crashed by 9432.38% in 2021 and then skyrocketed by 2091583.79% in 2022.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Accumulated Expenses stood at $22162.0 in 2021, then skyrocketed by 20915.84% to $4.7 million in 2022, then skyrocketed by 41.65% to $6.6 million in 2023, then soared by 59.23% to $10.5 million in 2024, then skyrocketed by 46.3% to $15.4 million in 2025.
  • Its last three reported values are $15.4 million in Q3 2025, $12.4 million for Q2 2025, and $11.4 million during Q1 2025.